We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
BioNTech's COVID-19 vaccine (co-developed with Pfizer) has made headlines with the announcement of its 90% efficacy rate. But this early data is subject to change and the vaccine must pass rigorous testing by the Therapeutic Goods Administration’s (TGA) before it's approved for use in Australia.
BioNTech SE is a German biotechnology company founded in 2008. BioNTech's COVID-19 vaccine (co-developed with Pfizer) propelled the company into the spotlight in 2020 with the announcement of its 90% efficacy rate. As one of the front runners in the development of a successful global vaccine, BioNTech's share price has since surged more than 600% by June 2021.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Cheap broker fees
| 52-week range | US$65.72 - US$464 |
|---|---|
| 50-day moving average | US$358.614 |
| 200-day moving average | US$232.7218 |
| Target price | US$330.75 |
| PE ratio | 18.4692 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | US$18.056 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $333.48
| 1 week (2021-09-21) | -2.31% |
|---|---|
| 1 month (2021-08-27) | -6.97% |
| 3 months (2021-06-28) | 45.98% |
| 6 months (2021-03-26) | 248.25% |
| 1 year (2020-09-28) | 401.47% |
|---|
Valuing BioNTech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioNTech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioNTech's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, BioNTech shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
BioNTech's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.0697. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioNTech's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
BioNTech's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$5.6 billion (£4.1 billion).
The EBITDA is a measure of a BioNTech's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | US$7.8 billion |
|---|---|
| Operating margin TTM | 71.2% |
| Gross profit TTM | US$-222,037,000 |
| Return on assets TTM | 68.31% |
| Return on equity TTM | 133.85% |
| Profit margin | 52.41% |
| Book value | 22.465 |
| Market capitalisation | US$80.9 billion |
TTM: trailing 12 months
There are currently 2.1 million BioNTech shares held short by investors – that's known as BioNTech's "short interest". This figure is 2.4% up from 2.1 million last month.
There are a few different ways that this level of interest in shorting BioNTech shares can be evaluated.
BioNTech's "short interest ratio" (SIR) is the quantity of BioNTech shares currently shorted divided by the average quantity of BioNTech shares traded daily (recently around 6.2 million). BioNTech's SIR currently stands at 0.34. In other words for every 100,000 BioNTech shares traded daily on the market, roughly 340 shares are currently held short.
However BioNTech's short interest can also be evaluated against the total number of BioNTech shares, or, against the total number of tradable BioNTech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioNTech's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 BioNTech shares in existence, roughly 10 shares are currently held short) or 0.0273% of the tradable shares (for every 100,000 tradable BioNTech shares, roughly 27 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioNTech.
Find out more about how you can short BioNTech stock.
We're not expecting BioNTech to pay a dividend over the next 12 months.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Steps to owning and managing China Evergrande Group shares from Australia.
Steps to owning and managing Incannex Healthcare from Australia.
Steps to owning and managing Scotts Miracle Go shares from Australia.
Steps to owning and managing Rubicon Water shares.
Steps to owning and managing Endeavour Group Limited shares from Australia.
Steps to owning and managing BetaShares Legg Mason Emerging Markets Fund (Managed Fund) ETF units.
Steps to owning and managing eInvest Future Impact Small Caps Fund (Managed Fund) ETF units.
Steps to owning and managing VanEck Vectors MSCI International Value ETF units.
Steps to owning and managing VanEck Vectors MSCI International Small Companies Quality ETF units
Steps to owning and managing Montaka Global Extension Fund (Quoted Managed Hedge Fund) ETF units
